Conclusion
nephrotoxicities, toxicities
OVARIAN CANCER
We contribute to the growing pool of literature showing that ST abrogates nephrotoxicities induced by HIPEC with cisplatin and does not result in reduced PFS. The lack of renal toxicities associated with ST use and its stability in serum Cr, in contrast to the significant increase in serum Cr in patients without ST use, underscore the importance nephroprotection in HIPEC with cisplatin for patients with ovarian cancer.